登录 | 注册    关注公众号  
微信公众号
搜索
 >  Protein>IL-3 >IL3-H52H9

Human IL-3 Protein, His Tag (MALS verified)

分子别名(Synonym)

IL3,MCGF,MGC79398,MGC79399,MULTI-CSF,Interleukin-3

表达区间及表达系统(Source)

Human IL-3 Protein, His Tag (IL3-H52H9) is expressed from human 293 cells (HEK293). It contains AA Ala 20 - Phe 152 (Accession # P08700-1).

Predicted N-terminus: Ala 20

Request for sequence

蛋白结构(Molecular Characterization)

IL-3 Structure

This protein carries a polyhistidine tag at the C-terminus.

The protein has a calculated MW of 17.0 kDa. The protein migrates as 25-35 kDa under reducing (R) condition (SDS-PAGE) due to glycosylation.

内毒素(Endotoxin)

Less than 0.3 EU per μg by the LAL method.

无菌(Sterility)

Negative

纯度(Purity)

>90% as determined by SDS-PAGE.

制剂(Formulation)

Lyophilized from 0.22 μm filtered solution in PBS, pH7.4 with trehalose as protectant.

Contact us for customized product form or formulation.

重构方法(Reconstitution)

Please see Certificate of Analysis for specific instructions.

For best performance, we strongly recommend you to follow the reconstitution protocol provided in the CoA.

存储(Storage)

For long term storage, the product should be stored at lyophilized state at -20°C or lower.

Please avoid repeated freeze-thaw cycles.

This product is stable after storage at:

  1. -20°C to -70°C for 12 months in lyophilized state;
  2. -70°C for 3 months under sterile conditions after reconstitution.

质量管理控制体系(QMS)

  1. 质量管理体系(ISO, GMP)
  2. 质量优势
  3. 质控流程
 

电泳(SDS-PAGE)

IL-3 SDS-PAGE

Human IL-3 Protein, His Tag on SDS-PAGE under reducing (R) condition. The gel was stained with Coomassie Blue. The purity of the protein is greater than 90%.

SEC-MALS

IL-3 SEC-MALS

The purity of Human IL-3 Protein, His Tag (Cat. No. IL3-H52H9) is more than 85% and the molecular weight of this protein is around 20-30 kDa verified by SEC-MALS.

Report

 

活性(Bioactivity)-ELISA

IL-3 ELISA

Immobilized Human IL-3 Protein, His Tag (Cat. No. IL3-H52H9) at 5 μg/mL (100 μL/well) can bind Human IL-3 R alpha Protein, Llama IgG2b Fc Tag (Cat. No. ILA-H5255) with a linear range of 0.039-2.5 μg/mL (QC tested).

Protocol

 

活性(Bioactivity)-BLI

IL-3 BLI

Loaded Human IL-3 R alpha, Fc Tag (Cat. No. ILA-H5252) on Protein A Biosensor, can bind Human IL-3 Protein, His Tag (Cat. No. IL3-H52H9) with an affinity constant of 0.71 μM as determined in BLI assay (ForteBio Octet Red96e) (QC tested).

Protocol

IL-3 BLI

Loaded Biotinylated Human IL-3 R alpha, Fc,Avitag (Cat. No. ILA-H82F3) on SA Biosensor, can bind Human IL-3 Protein, His Tag (Cat. No. IL3-H52H9) with an affinity constant of 0.35 μM as determined in BLI assay (ForteBio Octet Red96e) (Routinely tested).

Protocol

 
评论(1)
  1. 178XXXXXXX7
  2. 1人赞
  3. 主要用于单克隆抗体的筛选。实验采用了终点法酶联免疫吸附测定抗原抗体之间的相互作用强弱。通过对各个抗体进行亲和力测定来评估抗体的性能,筛选出符合预期的目标抗体。
  4. 2021-12-6
 
ACRO质量管理体系
 
 

背景(Background)

Interleukin 3 is also known as IL-3, is a protein that in humans is encoded by the IL3 gene. Interleukin-3 (IL-3) is an interleukin, a type of biological signal (cytokine) that can improve the body's natural response to disease as part of the immune system. It acts by binding to the interleukin-3 receptor. The IL-3 receptor is a heterodimer of the IL-3 specific α-chain and the common β-chain, βc, which is also used by GM-CSF and IL-5. [3] Binding of IL-3 can also involve substitution of the βc by a βIL-3-chain that appears to be specific for IL-3 . Binding of IL-3 to its cognate receptor(s) induces activation of Jak2, phosphorylation of multiple Stats, and the PI3K/Akt pathway. IL-3 may play an important role in the development of airway inflammation associated with asthma. The human IL-3 gene encodes a protein 152 amino acids long, and the naturally occurring IL-3 is glycosylated. The human IL-3 gene is located on chromosome 5, only 9 kilobases from the GM-CSF gene, and its function is quite similar to GM-CSF.

 

前沿进展

Immunotherapies Targeting CD123 and CD303: A New Frontier in Treating Blastic Plasmacytoid Dendritic Cell Neoplasm
Galati, Zanotta, Florio et al
Int J Mol Sci (2025) 26 (6)
Abstract: Blastic plasmacytoid dendritic cell neoplasm (BPDCN) is a rare and aggressive hematologic malignancy characterized by the overexpression of CD123 and CD303 surface antigens. These molecular markers play a crucial role in diagnosing diseases and developing targeted therapies. Traditional treatment options for BPDCN have demonstrated limited effectiveness, highlighting the need for new and innovative therapeutic strategies. Recent advances in immunotherapy, particularly therapeutic monoclonal antibodies, bispecific T-cell engagers, and CAR T-cell therapy, have provided promising alternatives. Tagraxofusp, the first FDA-approved CD123-targeted therapy, has significantly improved patient outcomes. Additionally, emerging CD303-targeting strategies offer the potential for further advancements. Despite these breakthroughs, challenges such as treatment resistance and toxicity remain. This review explores the latest developments in BPDCN treatment, emphasizing the potential of CD123 and CD303 as targets for precision medicine interventions. The ongoing evolution of targeted immunotherapies holds promise for improving patient survival and redefining treatment paradigms in hematologic malignancies.
Refining the interactions between microglia and astrocytes in Alzheimer's disease pathology
Chen, Xu, Wang et al
Neuroscience (2025) 573, 183-197
Abstract: Microglia and astrocytes are central to the pathogenesis and progression of Alzheimer's Disease (AD), working both independently and collaboratively to regulate key pathological processes such as β-amyloid protein (Aβ) deposition, tau aggregation, neuroinflammation, and synapse loss. These glial cells interact through complex molecular pathways, including IL-3/IL-3Ra and C3/C3aR, which influence disease progression and cognitive decline. Emerging research suggests that modulating these pathways could offer therapeutic benefits. For instance, recombinant IL-3 administration in mice reduced Aβ plaques and improved cognitive functions, while C3aR inhibition alleviated Aβ and tau pathologies, restored synaptic function, and corrected immune dysregulation. However, the effects of these interactions are context-dependent. Acute C3/C3aR activation enhances microglial Aβ clearance, whereas chronic activation impairs it, highlighting the dual roles of glial signaling in AD. Furthermore, C3/C3aR signaling not only impacts Aβ clearance but also modulates tau pathology and synaptic integrity. Given AD's multifactorial nature, understanding the specific pathological environment is crucial when investigating glial cell contributions. The interplay between microglia and astrocytes can be both neuroprotective and neurotoxic, depending on the disease stage and brain region. This complexity underscores the need for targeted therapies that modulate glial cell activity in a context-specific manner. By elucidating the molecular mechanisms underlying microglia-astrocyte interactions, this research advances our understanding of AD and paves the way for novel therapeutic strategies aimed at mitigating neurodegeneration and cognitive decline in AD and related disorders.Copyright © 2025. Published by Elsevier Inc.
Lienal Polypeptide Decreases Immune Thrombocytopenia in a Mouse Model by Upregulating Cytokine Production and Increasing the Levels of CD4+, CD8+, and T Regulatory Cells
Yue, Xie, Wang et al
J Interferon Cytokine Res (2025)
Abstract: Primary immune thrombocytopenia (ITP) is a condition marked by immune-mediated inadequate platelet production or excessive destruction. This study investigates the effects of Lienal polypeptide injection (LP) on T lymphocyte subgroups in the spleen and thymus, megakaryocyte counts in the bone marrow, and cytokine levels related to megakaryocyte development in mice with antibody-induced ITP, aiming to elucidate potential therapeutic mechanisms. We first assessed the effects of LP on Meg-01 megakaryocytic cells regarding proliferation, apoptosis, and differentiation using Methylthiazolyldiphenyl-tetrazolium bromide (MTT) assays, Western blot analysis, and flow cytometry for apoptosis and CD41 expression as a differentiation marker. Following this, LP was administered intraperitoneally at 60 mg/(kg·d) for 11 days to ITP mice. We quantified peripheral blood platelets and bone marrow megakaryocytes, measured spleen and thymus indices, and assessed serum levels of stem cell factor (SCF), interleukin-3 (IL-3), interleukin-6 (IL-6), and platelet factor-4 (PF-4) via enzyme-linked immunosorbent assay (ELISA). Flow cytometry quantified T-helper cells (CD4+), cytotoxic T cells (CD8+), and regulatory T cells (Tregs). LP significantly induced apoptosis in Meg-01 cells while not markedly affecting differentiation. In ITP mice, LP effectively prevented platelet decline without affecting megakaryocyte counts or maturity. Increased SCF, IL-3, and IL-6 levels, alongside decreased PF-4 levels, correlated with enhanced platelet production. Moreover, CD4+/CD8+ ratios and Treg populations increased, contributing to reduced platelet destruction. In conclusion, LP exerts a protective effect in ITP by modulating SCF, IL-3, IL-6, and PF-4 levels and restoring the balance of T cell subtypes, elucidating its therapeutic potential.
Carbon Dioxide Selectivity over Ethane in Promising Bis Tri (Fluoromethylsulfonyl) Imide-Based Ionic Liquids
Quaye, Henni, Shirif
Molecules (2025) 30 (5)
Abstract: This research addresses the critical challenge of CO2 capture by exploring innovative ways to avoid ethane (C2H6) co-absorption in natural gas sweetening operations. The solubility of Ethane (C2H6) was measured in three ionic liquids (ILs) with similar anions, 1-decyl-3-methyl imidazolium bis (trifluoro methylsulfonyl imide) [IL-1], 1-hexadecyl-3-methylimidazolium bis (trifluoro methylsulfonyl imide) [IL-2], and triethytetra-decyl ammonium bis (trifluoromethylsulfonyl imide) [IL-3]. The solubility experiments were investigated at 303.15 K and 343.15 K with pressures reaching 1.2 MPa. Among the ILs, [IL-2] exhibited the highest ethane absorption capacity due to its extended alkyl chain. The Peng-Robinson equation of state (PR-EoS) and three (3) distinct mixing rules provided robust correlations for the solubility data. Results demonstrate the inferior performance of [IL-1], [IL-2], and [IL-3] compared to Selexol/Genosorb 1753. The selectivity of Ethane (C2H6) over CO2 was determined, with the overall selectivity ranking as follows: [IL-1] > [IL-3] > [IL-2]. A comparison of these selectivity values with published IL data indicated that these three ILs are most effective when used in applications targeting CO2 capture in the absence of Ethane (C2H6), such as in the case of flue gas. They will most probably be used with an amine blend. Additionally, the Enthalpy and entropy of absorption provided valuable insights, demonstrating Ethane's weaker interactions and lower solubility than CO2. These findings emphasize the critical role of IL structure in determining ethane solubility and highlight the potential of customized ILs for optimizing gas-separation processes.
Showing 1-4 of 12735 papers.
Powered by BizGenius
 
 
货号/价格
文档
联系电话:
+86 400-682-2521(全国)
010-53681107(北京)
021-50850665(上海)
运输方式
订单邮箱:
order.cn@acrobiosystems.com
技术支持邮箱:
tech.cn@acrobiosystems.com
IL-3靶点信息
英文全称:Interleukin-3
中文全称:白细胞介素-3
种类:
上市药物数量:0详情
临床药物数量:0详情
最高研发阶段:无进展
查看更多信息
前沿进展
点击查看详细

消息提示

请输入您的联系方式,再点击提交!

确定